We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Rocket Pharmaceuticals Inc | NASDAQ:RCKT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 22.83 | 22.31 | 24.50 | 87 | 14:03:49 |
From May 2023 to May 2024
By Ben Glickman
Rocket Pharmaceuticals said it had reached alignment with the Food and Drug Administration on its Phase 2 trial of its treatment for Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study would evaluate the use of RP-A501 to treat 12 patients with Danon disease, a fatal cardiomyopathy with no cure. The Phase 2 trial will be an open-label study with a biomarker-based co-primary endpoint assessed after 12 months, the company said.
The trial will support accelerated approval of Rocket's treatment by the FDA.
The company said it expected to file its Clinical Trial Application/Investigational Medicinal Product Dossier for RP-A501, which will allow for studies to take place in the European Union in the third quarter.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 12, 2023 16:40 ET (20:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Rocket Pharmaceuticals Chart |
1 Month Rocket Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
